Liver-related death among HIV/hepatitis C virus-co-infected individuals: Implications for the era of directly acting antivirals
- Grint D.
- Peters L.
- Rockstroh J. K.
- Rakmanova A.
- Trofimova T.
- Lacombe K.
- Karpov I.
- Galli M.
- Domingo P.
- Kirk O.
- Lundgren J. D.
- Mocrofta A.
- Losso M.
- Kundro M.
- Vetter N.
- Zangerle R.
- Karpov I.
- Vassilenko A.
- Mitsura V. M.
- Paduto D.
- Clumeck N.
- De Wit S.
- Delforge M.
- Florence E.
- Vandekerckhove L.
- Hadziosmanovic V.
- Kostov K.
- Begovac J.
- Machala L.
- Jilich D.
- Sedlacek D.
- Nielsen J.
- Kronborg G.
- Benfield T.
- Larsen M.
- Gerstoft J.
- Katzenstein T.
- Hansen A. -B. E.
- Skinhoj P.
- Pedersen C.
- Moller N. F.
- Ostergaard L.
- Dragsted U. B.
- Nielsen L. N.
- Zilmer K.
- Smidt J.
- Ristola M.
- Katlama C.
- Viard J. -P.
- Girard P. -M.
- Vanhems P.
- Pradier C.
- Dabis F.
- Neau D.
- Duvivier C.
- Rockstroh J.
- Schmidt R.
- Van Lunzen J.
- Degen O.
- Stellbrink H. J.
- Stefan C.
- Bogner J.
- Fatkenheuer G.
- Chkhartishvili N.
- Kosmidis J.
- Gargalianos P.
- Xylomenos G.
- Perdios J.
- Sambatakou H.
- Banhegyi D.
- Gottfredsson M.
- Mulcahy F.
- Yust I.
- Turner D.
- Burke M.
- Shahar E.
- Hassoun G.
- Elinav H.
- Haouzi M.
- Sthoeger Z. M.
- Monforte A. D.
- Esposito R.
- Mazeu I.
- Mussini C.
- Pristera R.
- Mazzotta F.
- Gabbuti A.
- Vullo V.
- Lichtner M.
- Zaccarelli M.
- Antinori A.
- Acinapura R.
- D'Offizi G.
- Lazzarin A.
- Castagna A.
- Gianotti N.
- Galli M.
- Ridolfo A.
- Rozentale B.
- Uzdaviniene V.
- Staub T.
- Hemmer R.
- Reiss P.
- Ormaasen V.
- Maeland A.
- Bruun J.
- Knysz B.
- Gasiorowski J.
- Inglot M.
- Horban A.
- Bakowska E.
- Grzeszczuk A.
- Flisiak R.
- Parczewski M.
- Pynka M.
- Maciejewska K.
- Beniowski M.
- Mularska E.
- Smiatacz T.
- Jablonowska E.
- Malolepsza E.
- Wojcik K.
- Mozer-Lisewska I.
- Doroana M.
- Caldeira L.
- Mansinho K.
- Maltez F.
- Radoi R.
- Oprea C.
- Babes V.
- Rakhmanova A.
- Rakhmanova A.
- Trofimora T.
- Khromova I.
- Kuzovatova E.
- Jevtovic D.
- Shunnar A.
- Stanekova D.
- Tomazic J.
- Moreno S.
- Rodriguez J. M.
- Clotet B.
- Jou A.
- Paredes R.
- Tural C.
- Puig J.
- Bravo I.
- Gatell J. M.
- Miro J. M.
- Domingo P.
- Gutierrez M.
- Mateo G.
- Sambeat M. A.
- Laporte J. M.
- Blaxhult A.
- Flamholc L.
- Thalme A.
- Sonnerborg A.
- Ledergerber B.
- Weber R.
- Cavassini M.
- Calmy A.
- Furrer H.
- Battegay M.
- Elzi L.
- Schmid P.
- Kravchenko E.
- Chentsova N.
- Frolov V.
- Kutsyna G.
- Baskakov I.
- Servitskiy S.
- Kuznetsova A.
- Kyselyova G.
- Gazzard B.
- Johnson A. M.
- Simons E.
- Edwards S.
- Phillips A.
- Johnson M. A.
- Mocroft A.
- Orkin C.
- Weber J.
- Scullard G.
- Fisher M.
- Leen C.
DOIAbstract
Background: Potent, less toxic, directly acting antivirals (DAAs) for treatment of hepatitis C virus (HCV) infection promise to improve HCV cure rates among HIV/ HCV-co-infected individuals. However, the costs of treatment will necessitate prioritization of those at greatest risk of liver-related death (LRD) for therapy. This study aims to provide guidance on who should be prioritized for DAA treatment. Methods: Three thousand, nine hundred and forty-one HCV antibody-positive PSHREG and FIB-4 are names not acronyms (EuroSIDA) patients with follow-up after 1 January 2000 were included, with causes of death classified using Coding causes of Death in HIV (CoDe) methodology. Crude death rates, competing-risks Cox proportional- hazards models an...
Add to ORKG